Aplastic anemia

Czech version

Authors: Jaroslav Čermák ^1,2
Authors‘ workplace: Ústav klinické a experimentální hematologie 1. LF UK, Praha ¹; Ústav hematologie a krevní transfuze, Praha ²
Published in: Vnitř Lék 2018; 64(5): 501-507
Category:

Overview

Aplastic anemia – bone marrow failure (AA) is defined as pancytopenia with hypocellular bone marrow without signs of marrow fibrosis or of presence of abnormal cells. Recent studies showed that most of AA cases might be mediated by immune mechanisms. Toxic agent leads to expression of neoantigens or cryptic antigens on the surface of pluripotent hematopoietic stem cells with subsequent activation of immune effector cells and induction of stem cell apoptosis. Histopathological findings obtained from bone marrow biopsy are crucial for diagnosis of AA. Hypoplastic MDS, PNH, hairy cell leukemia and late manifestation of congenital cytopenias must be excluded in differential diagnosis. Allogeneic stem cell transplantation from HLA matched related donor or combined immune suppression represent the first line treatment for patients with severe AA (SAA). Transplantation from unrelated donor may be a second line treatment for patients who failed to respond to immunosuppressive therapy. Recent studies showed eltrombopag or its combination with immune supression as an effective therapeutic approach to AA patients. Up to 15 % of AA patients may later develop PNH, MDS or acute leukemia. An influence of disturbed immune mechanisms as well as of immunosuppressive treatment on the development of clonal proliferation is currently discussed.

Key words:

aplastic anemia – diagnosis – eltrombopag – immunosuppression – transplantation – treatment

Sources

Camitta BM, Rappeport JM, Parkman R et al. Selection of patients for bone marrow transplantation in severe aplastic anemia. Blood 1975; 45(3): 355–363.
Bacigalupo A, Hows J, Gluckman E et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. Br J Haematol 1988; 70(2): 177–182.
Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108(8): 2509–2519. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2006–03–010777>.
Calado RT, Young NS. Telomere diseases. N Engl J Med 2009; 361(24): 2353–2365. <http://dx.doi.org/10.1056/NEJMra0903373>.
Young NS. Current concepts in the pathophysiology and treatment of aplastic anemia. Hematology 2014; Am Soc Hematol Educ Program 2014: 76–81. Dostupné z DOI: <http://doi: 10.1182/asheducation-2013.1.76>.
Dameshek W. Riddle: what do aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH) and “hypoplastic” leukemia have in common? Blood 1967; 30(2): 251–254.
Tichelli A, Gratwohl A, Wursch A et al. Late haematological Complications in severe aplastic anaemia. Br J Haematol 1998; 69(3): 413–418.
Frickhofen N, Heimpel H, Kaltwasser JP et al. German Aplastic Anemia Study, G. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003; 101(4): 1236–1242. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2002–04–1134>.
Stanley N, Olson TS, Babushok DV. Recent advances in understanding clonal haematopoiesis in aplastic anaemia. Br J Haematol 2017; 177(4): 509–525. Dostupné z DOI: <http://dx.doi.org/10.1111/bjh.14510>.
Maciejewski JP, Risitano AM, Nunez O et al. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 2002; 99(9): 3129–3135.
Kulasekararaj AG, Jiang J, Smith AE et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood 2014; 124(17): 2698–2704. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2014–05–574889>.
Yoshizato T, Dumitriu B, Hosokawa K et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med 2015; 373(1): 35–47. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1414799>.
Cooper JN, Young NS. Clonality in context: hematopoietic clones in their marrow Environment. Blood 2017; 130(22): 2363–2372. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2017–07–794362>.
Killick SB, Brown N, Cavenagh J et al. Guidelines for the diagnosis and treatment of adult aplastic anemia. Br J Haematol 2016; 172(2): 187–207. Dostupné z DOI: <http://dx.doi.org/10.1111/bjh.13853>. Erratum in Corrigendum. [Br J Haematol. 2016].
Afable MG, Tiu RV, Maciejewski JP. Clonal evolution in aplastic anemia. Hematology 2011; Am Soc Hematol Educ Program 2011; 2011: 90–95. Dostupné z DOI: <http://dx.doi.org/10.1182/asheducation-2011.1.90>.
Bacigalupo A. How I treat aplastic anemia. Blood 2017; 129(11): 1428–1436. <http://dx.doi.org/10.1182/blood-2016–08–693481>.
Gupta V, Eapen M, Brazauskas R et al. Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica 2010; 95(12): 2119–2125. Dostupné z DOI: <http://dx.doi.org/10.3324/haematol.2010.026682>.
Locasciulli A, Oneto R, Bacigalupo A et al. [Severe Aplastic Anemia Working Party of The European Blood and Marrow Transplant Group]. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2007; 92(1): 11–18.
Bacigalupo A, Socie G, Schrezenmeier H et al. [Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (WPSAA-EBMT)]. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica 2012; 97(8): 1142–1148. Dostupné z DOI: <http://dx.doi.org/10.3324/haematol.2011.054841>.
Bacigalupo A, Socie G, Hamladji RM et al. [Aplastic Anemia Working Party of the European Group for Blood Marrow Transplantation]. Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis. Haematologica 2015; 100(5): 696–702. Dostupné z DOI: <http://dx.doi.org/10.3324/haematol.2014.115345>.
Bacigalupo A, Bruno B, Saracco P et al. [European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO)]. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. Blood 2000; 95(6): 1931–1934.
Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood 2012; 120(6): 1185–1196. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2011–12–274019>.
Scheinberg P, Nunez O, Weinstein B et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011; 365(5): 430–438. <http://dx.doi.org/10.1056/NEJMoa1103975>.
Rosenfeld SJ, Kimball J, Vining D et al. Intensive immunosuppression with Antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood 1995; 85(11): 3058–3065.
Olnes MJ, Scheinberg P, Calvo KR et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 2012; 367(1): 11–19. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1200931>. Erratum in N Engl J Med 2012; 367(3): 284.
Marsh JCW, Mufti GJ. Eltrombopag, a stem cell cookie? Blood 2014; 123(12): 1774–1775. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2014–02–553404>.
Desmond R, Townsley DM, Dumitriu B et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood 2014; 123(12): 1818–1825. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2013–10–534743>.
Townsley DM, Scheinberg P, Winkler T et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med 2017; 376(16): 1540–1550. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1613878>.